Amgen (NASDAQ:AMGN) (NASDAQ: AMGN) is a leading global biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen has built its reputation on pioneering biotechnology and developing innovative therapies for serious illnesses. Over the decades, the company has leveraged recombinant DNA technology and protein engineering to discover, develop and manufacture human therapeutics at scale.
Amgen’s core business focuses on biologic medicines that address oncology, nephrology, bone health, cardiovascular disease and inflammation. Flagship products include Neulasta and Neupogen, which help support cancer patients undergoing chemotherapy, and Prolia and XGEVA, used in the treatment of osteoporosis and skeletal complications. The company also markets Repatha for cholesterol management and has an expanding oncology portfolio that features novel antibody-drug conjugates and immune-modulating agents.
With operations spanning North America, Europe, Asia Pacific and emerging markets, Amgen maintains a robust global footprint. Its network includes research and development facilities, manufacturing sites and commercial operations in more than 100 countries. This international presence supports strategic partnerships, local market access and a diversified revenue base, strengthening Amgen’s ability to deliver therapies to patients worldwide.
Under the leadership of Chairman and Chief Executive Officer Robert A. Bradway, Amgen continues to invest heavily in R&D and pipeline expansion. The company prioritizes collaborations with academic institutions, biotechnology firms and healthcare organizations to accelerate innovation. Supported by a strong leadership team and a commitment to scientific excellence, Amgen remains focused on advancing next-generation therapies and delivering value to patients and shareholders alike.
